SLP

+ Watchlist + Portfolio

Simulations Plus, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $18.37
52-Week Range: $11.09 – $21.01
Market Cap: $371.73M
P/E (TTM): 45.95
EPS (TTM): 0.40
Dividend Yield: —

Advanced Metrics

Price/Book: 2.67
PEG Ratio: 9.88
Return on Equity: 6.17%
Return on Assets: 5.48%
Gross Margin: 63.38%
Operating Margin: 22.84%
Profit Margin: 9.88%
Current Ratio: 5.54
Debt/Equity: 0.00
Total Debt: $487.00K
Free Cash Flow: $18.41M
Revenue Growth: 7.50%
Earnings Growth: —
Enterprise Value: $322.23M

SLP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$53.91M	$59.58M	$70.01M	$79.18M
Cost of Revenue	$10.82M	$11.63M	$26.86M	$32.96M
Gross Profit	$43.08M	$47.95M	$43.15M	$46.22M
Research & Development	$3.21M	$4.50M	$5.75M	$6.88M
Selling, General & Admin	$24.96M	$34.22M	$31.27M	$32.84M
Operating Expenses	$28.17M	$38.72M	$37.02M	$39.73M
Operating Income	$14.91M	$9.22M	$6.13M	$6.49M
EBITDA	$18.48M	$13.06M	$11.80M	$14.70M
Pretax Income	$15.12M	$11.70M	$12.41M	-$69.38M
Income Tax	$2.63M	$1.73M	$2.46M	-$4.66M
Net Income	$12.48M	$9.96M	$9.95M	-$64.72M
Diluted EPS	0.60	0.49	0.49	-3.22
Diluted Shares	20.75M	20.46M	20.30M	20.10M

SLP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$51.57M	$57.52M	$10.31M	$30.85M
Receivables	$13.79M	$10.20M	$9.14M	$9.72M
Current Assets	$146.79M	$130.37M	$39.34M	$51.55M
Total Assets	$188.38M	$186.10M	$196.64M	$131.94M
Current Liabilities	$7.74M	$11.99M	$12.07M	$6.72M
Total Debt	$1.40M	$1.20M	$1.01M	$616.00K
Total Liabilities	$10.13M	$16.07M	$14.21M	$7.13M
Retained Earnings	$40.04M	$25.20M	$30.35M	-$34.36M
Shareholders' Equity	$178.25M	$170.03M	$182.43M	$124.80M
Working Capital	$139.06M	$118.39M	$27.27M	$44.82M

SLP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$17.90M	$21.86M	$13.32M	$18.13M
Capital Expenditure	-$3.97M	-$4.27M	-$4.30M	-$3.72M
Free Cash Flow	$13.93M	$17.58M	$9.02M	$14.40M
Depreciation & Amortisation	$3.57M	$3.84M	$5.67M	$8.21M
Stock-Based Compensation	$3.04M	$4.83M	$6.54M	$6.35M
Investing Cash Flow	$4.30M	$7.37M	-$53.97M	$3.56M
Financing Cash Flow	-$7.62M	-$23.27M	-$6.57M	-$1.15M
Dividends Paid	-$4.85M	-$4.81M	-$4.80M	$0.00
Share Repurchases	$0.00	-$20.00M	$0.00	$0.00
Net Change in Cash	$14.58M	$5.96M	-$47.21M	$20.54M

SLP Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$20.36M	$17.46M	$18.42M	$24.29M	$21.89M
Cost of Revenue	$7.33M	$7.62M	$7.53M	$8.15M	$6.76M
Gross Profit	$13.03M	$9.84M	$10.89M	$16.14M	$15.13M
Research & Development	$1.22M	$1.68M	$2.98M	$3.47M	$3.41M
Selling, General & Admin	$8.82M	$7.51M	$7.20M	$7.04M	$7.22M
Operating Expenses	$10.04M	$9.19M	$10.18M	$10.51M	$10.63M
Operating Income	$3.00M	$659.00K	$713.00K	$5.63M	$4.50M
EBITDA	$5.31M	$2.01M	$2.06M	$7.18M	$5.87M
Pretax Income	-$74.04M	$889.00K	$970.00K	$5.89M	$4.81M
Income Tax	-$6.73M	$1.57M	$294.00K	$1.35M	$1.23M
Net Income	-$67.32M	-$681.00K	$676.00K	$4.54M	$3.58M
Diluted EPS	-3.35	—	0.03	0.22	0.18
Diluted Shares	20.11M	—	20.22M	20.24M	20.24M

SLP Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$26.95M	$30.85M	$30.19M	$25.73M	$35.32M
Receivables	$14.78M	$9.72M	$12.15M	$18.17M	$17.20M
Current Assets	$51.77M	$51.55M	$58.14M	$67.56M	$75.13M
Total Assets	$134.36M	$131.94M	$137.83M	$146.48M	$152.98M
Current Liabilities	$10.13M	$6.72M	$10.34M	$12.34M	$13.57M
Total Debt	$719.00K	$616.00K	$557.00K	$508.00K	$487.00K
Total Liabilities	$10.58M	$7.13M	$10.72M	$12.71M	$13.94M
Retained Earnings	-$33.68M	-$34.36M	-$33.69M	-$29.15M	-$25.58M
Shareholders' Equity	$123.78M	$124.80M	$127.11M	$133.77M	$139.03M
Working Capital	$41.64M	$44.82M	$47.80M	$55.22M	$61.56M

SLP Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$8.14M	$5.59M	$4.23M	$6.41M	$8.71M
Capital Expenditure	-$1.09M	-$791.00K	-$900.00K	-$832.00K	-$761.00K
Free Cash Flow	$7.05M	$4.80M	$3.33M	$5.58M	$7.95M
Depreciation & Amortisation	$2.32M	$1.35M	$1.35M	$1.55M	$1.37M
Stock-Based Compensation	$1.41M	$1.52M	$1.61M	$1.62M	$1.66M
Investing Cash Flow	$7.81M	-$1.79M	-$4.90M	-$11.35M	$878.00K
Financing Cash Flow	$7.00K	$107.00K	$2.00K	$474.00K	$10.00K
Dividends Paid	$0.00	$0.00	—	—	—
Net Change in Cash	$15.96M	$3.90M	-$664.00K	-$4.46M	$9.60M

Market Snapshot

About

Simulations Plus, Inc. develops software for pharmaceutical research and development, providing simulation and modeling tools used in drug discovery and development. The company offers solutions for predicting drug properties, optimizing formulations, and supporting regulatory submissions. Simulations Plus serves pharmaceutical companies, biotechnology firms, and academic institutions worldwide with advanced scientific software and consulting services.